BioNTech signs collaboration agreement with Pfizer Inc. to develop mRNA-based vaccines for prevention of influenza

BioNTech signs collaboration agreement with Pfizer Inc. to develop mRNA-based vaccines for prevention of influenza

Under the agreement, BioNtech will receive USD 120 in upfront, equity and near-term research payments from Pfizer. Furthermore, BioNTech will be eligible to receive up to USD 305 in potential development, regulatory and commercial milestone payments and up to double-digit royalties.

The BioNTech press release can be found in the download area on the right.

Please click here for more information on BioNTech.

Provider 

Downloads